NCT00358449 - Intravenous Mepolizumab In Children With Eosinophilic Esophagitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2006

Primary Completion Date

November 25, 2008

Study Completion Date

November 25, 2008

Conditions

Oesophagitis, Eosinophilic

Interventions

DRUG

mepolizumab

Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.

Trial Locations (29)

4029

GSK Investigational Site, Brisbane

10029

GSK Investigational Site, New York

23507

GSK Investigational Site, Norfolk

30322

GSK Investigational Site, Atlanta

33613

GSK Investigational Site, Tampa

35205

GSK Investigational Site, Birmingham

45229

GSK Investigational Site, Cincinnati

46202

GSK Investigational Site, Indianapolis

47713

GSK Investigational Site, Evansville

48075

GSK Investigational Site, Southfield

48098

GSK Investigational Site, Troy

53215

GSK Investigational Site, Milwaukee

55402

GSK Investigational Site, Minneapolis

57108

GSK Investigational Site, Sioux Falls

62794

GSK Investigational Site, Springfield

63104

GSK Investigational Site, St Louis

64108

GSK Investigational Site, Kansas City

75230

GSK Investigational Site, Dallas

75235

GSK Investigational Site, Dallas

92123

GSK Investigational Site, San Diego

01655

GSK Investigational Site, Worcester

L8N 3Z5

GSK Investigational Site, Hamilton

K7L 5G2

GSK Investigational Site, Kingston

N6A 5W9

GSK Investigational Site, London

H3T 1C5

GSK Investigational Site, Montreal

L12 2AP

GSK Investigational Site, Liverpool

WC1N 3JH

GSK Investigational Site, London

S10 2TH

GSK Investigational Site, Sheffield

WD18 0HB

GSK Investigational Site, Watford